Renal disease News and Research

RSS

New study shows preoperative statin therapy protects patients undergoing elective AAA repair

Preoperative statin therapy has a protective effect on patients undergoing elective abdominal aortic aneurysm repair that reduces risk and subsequent total hospital costs according to a new study from researchers at the East Carolina Heart Institute in Greenville, North Carolina.

20 May 2010

Experts address fundamental questions related to renal failure in ICU

Despite the fact that recent medical advances have allowed healthcare professionals to stabilize patients who would have otherwise died, many stabilized patients later develop organ system failure. In fact, acute renal failure is one of the biggest threats to critically ill patients: forty percent of patients with this condition die.

14 May 2010

Nephros reports 57% increase in revenues for first-quarter 2010

Nephros, Inc. announced today financial results for the three months ended March 31, 2010.

14 May 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceutical Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

7 May 2010

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

6 May 2010

Rockwell Medical first-quarter sales up 17.1%

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported first quarter 2010 results today.

5 May 2010

Researchers analyze spine surgery patients' existing comorbdities in relationship to hospital stay, costs

It is estimated that between 75 and 85 percent of all Americans will suffer from low back pain and/or neck pain at some point in their lives. An estimated 12 million Americans suffer from degenerative disc disease, with over one million patients undergoing surgery each year. The cost of treating back pain is currently estimated at more than $100 billion annually in the U.S. Many patients with back pain have comorbidities that impact spine surgery.

5 May 2010

Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure

Results of a new study found that the investigational triple combination therapy of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) demonstrated significantly greater mean reductions at week 12 in blood pressure (37.1/21.8 mm Hg versus 27.5 to 30.0/15.1-18.0 mm Hg LS Mean Reductions, P< 0.0001), as compared to corresponding dual combination therapy (dual components).

3 May 2010

Left ventricular mass may help predict future cardiovascular and renal outcomes: Study

Data presented today at the American Society of Hypertension, Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) indicate that in men with high cardiovascular risk, left ventricular mass may help better predict future cardiovascular and renal outcomes, including hemodialysis.

3 May 2010

LFA seeks grant applications from medical researchers to help advance understanding of lupus nephritis

The Lupus Foundation of America seeks grant applications from medical researchers to help advance the understanding of lupus nephritis, a serious and life-threatening complication of lupus that can affect as many as 40 percent of all people with lupus, and two-thirds of children with the disease.

24 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Screening urine dipstick to diagnose chronic kidney disease in children not cost-effective

The routine use of a screening urine dipstick to diagnose chronic kidney disease in healthy children is not a cost-effective test, confirm Penn State College of Medicine researchers, who validated an American Academy of Pediatrics recommendation.

16 Apr 2010

USRC to acquire DCA

U.S. Renal Care, Inc., a privately-held leading provider of outpatient dialysis services, and Dialysis Corporation of America, a leading provider of outpatient kidney dialysis centers, announced today that they have entered into a definitive merger agreement for USRC to acquire DCA.

15 Apr 2010

Genes influence chronic kidney disease risk: Research

A team of researchers from the United States and Europe has identified more than a dozen genes that may play a role in the etiology of common forms of kidney disease. The team, known as the CKDGen Consortium, examined common variations in DNA sequences in more than 65,000 individuals of European descent. Common variations in several genes were found to be more frequent among people with poor kidney function or chronic kidney disease than in those with normal kidney function.

13 Apr 2010

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Medinox, Inc. in Carlsbad, California and Orient Europharma in Taiwan announce today that they have entered into a partnering agreement to develop and market NOX-100, a new anti-hypotensive drug. Under the terms of the agreement, Orient Europharma holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia. Medinox retains the marketing rights in the United States, Japan and Europe.

12 Apr 2010

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

BeaconEquity.com announces an investment report featuring Keryx Biopharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 Apr 2010

Nephros' 2009 product revenues up 81%

Nephros, Inc. announced today financial results for the twelve month period ended December 31, 2009.

3 Apr 2010

Amherst Dialysis staff honored with End Stage Renal Disease Patient Safety Improvement Award

Laura Simms has spent 12 hours a week receiving hemodialysis treatment since last fall, when her kidneys failed as a result of high blood pressure. The 50-year-old Monroe resident says the staff at University of Virginia Health System's Amherst Dialysis clinic have become like family to her.

2 Apr 2010

New index developed to determine risk of death in patients with end-stage kidney disease

A new clinical prediction index has been developed to determine the risk of death in patients with end-stage kidney disease considering transplantation, states a Research article in CMAJ.

1 Apr 2010

Seniors with diabetes and dementia more likely to fall into Medicare Part D prescription drug plan

Among seniors, women and patients with diabetes and dementia are the most likely to fall into the Medicare Part D prescription drug plan "donut hole" - the gap occurring after beneficiaries reach their annual coverage limit and before catastrophic coverage kicks in - according to new research published online in the Journal of General Internal Medicine.

29 Mar 2010